Some of my posts are long, and investors are inclined not to...

Some of my posts are long, and investors are inclined not to read them....if they are too lengthly.

So thats the reason for multiple postings:

The company explain that attemps to replace injectable drugs with oral versions, usually fail because very small proteins are broken down by digestive enzymes. (thats the reason for injections....to avoid stomach acids).

MBP say they are developing a bigger (analog) version of peptide that has proven already to resist digestive enzyne breakdown. They have documentated animal trials in this regard.

This from their website: (in part means they can go into the manufacture of generic previously injectable only drug)

Metabolic's Oral Peptide Delivery Platform has the potential to be used by other companies developing peptide drugs. This could be a significant value driver for Metabolic if high and consistent oral activity can be demonstrated. About 40 peptide drugs are currently commercially available, about 10 are awaiting registration and 600-700 are in various stages of development, most of them injected drugs. If only a small proportion of these could be converted to oral drugs, as has been demonstrated with ACV1, this could provide a significant number of licensing opportunities for Metabolic and a possible medium-term cash flow. It could also be an important source of new drugs for in-house development by Metabolic.